News From our Center
Publication highlight: Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age
Oral immunotherapy has proven to be safe and effective for treating food allergies, and prior studies have suggested that higher clinical benefits are seen in younger individuals. However, how young can oral immunotherapy be safely introduced?
Highlights from Global Food Allergy Prevention Summit 2023: Early Treatment and Secondary Prevention of Food Allergy with Biologics
The Global Food Allergy Prevention Summit brings together international leaders in food allergy research to discuss the future of food allergy prevention. This year Dr. Sharon Chinthrajah discussed the use of biologics for the treatment and prevention of food allergy.
Highlights from PAAM Hybrid Conference: Biologics in food allergy
At the recent international Pediatric Allergy and Asthma Meeting (PAAM) held annually by the European Academy of Allergy and Clinical Immunology (EAACI), Sayantani (Tina) Sindher discussed the use of biologics for treating food allergy in children.
November 3, 2023
Highlights from Global Food Allergy Prevention Summit 2023: Early Oral Immunotherapy (OIT)
Another exciting talk at the Global Food Allergy Prevention Summit 2023 was Sayantani (Tina) Sindher’s discussion on early oral immunotherapy (OIT). OIT has proven to be safe and effective for the treatment of food allergy, however when should treatment be initiated?
Publication highlight: Treatment of food allergy: Oral immunotherapy, biologics, and beyond
Although oral immunotherapy is effective at treating food allergy, it has several limitations which include a slow time-frame, frequent although mostly mild adverse reactions, and patient anxiety. Increasing efforts are being placed on the study of biological therapeutics which target the underlying disease mechanisms of allergy which could not only improve the safety and effectiveness of oral immunotherapy, but also have the potential for the treatment of food allergy by themselves.
Highlights from The British Society for Allergy & Clinical Immunology (BSACI) Global Allergy Online Symposium: Conversations with patients about oral immunotherapy
At the recent international BSACI Global Allergy Online Symposium, Dr. Sharon Chinthrajah and Dr. Sayantani Sindher shared their discussions with patients who were interested in oral immunotherapy for food allergy. The decision to initiate oral immunotherapy is made after careful shared-decision making discussions between physicians, patients, and their families.
Publication highlight: Transitioning from epicutaneous to oral peanut immunotherapy
Epicutaneous immunotherapy (EPIT) is a food allergy immunotherapy strategy that uses a skin patch to train the immune system to tolerate food allergens. In comparison to the more widely used oral immunotherapy (OIT), EPIT is generally considered to be safer but provides less protection than OIT.
Publication highlight: Retail Food Equivalents for Post-Oral Immunotherapy Dosing in the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy in Food-Allergic Children and Adults (OUtMATCH) Clinical Trial
After the completion of oral immunotherapy or other immunotherapy strategies for food allergy, food allergic individuals are often advised to introduce small amounts of specific foods into their diet, however retail foods have different amounts of allergens than the doses they received during oral immunotherapy. So how much should they consume?
